1 active not recruiting, 1 completed, 1 recruiting, 1 terminated. 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Evorpacept (ALX148): new trials by email Literature Review of Evorpacept (ALX148) trials Research Report on Evorpacept (ALX148)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer Evorpacept (ALX148), Trastuzumab, Paclitaxel - Breast Cancer, Metastatic | Phase 2 | Recruiting | ALX Oncology Inc. | 120 | 2025-12-10 | 2026-09-25 |
| Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer Evorpacept (ALX148), Cetuximab, Pembrolizumab - Microsatellite Stable Metastatic Colorectal Cancer | Phase 2 | Terminated | University of Colorado, Denver | 19 | 2022-07-28 | 2026-09-03 |
| A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) Evorpacept (ALX148), Trastuzumab, Ramucirumab - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | ALX Oncology Inc. | 127 | 2022-01-15 | 2025-08-07 |
| A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) Evorpacept (ALX148), Pembrolizumab, Trastuzumab - Metastatic Cancer, Solid Tumor | Phase 1 | Completed | ALX Oncology Inc. | 174 | 2017-02-03 | 2025-08-01 |
Neoplasm Metastasis (2) · Breast Neoplasms (1) · Colorectal Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms (1) · Stomach Neoplasms (1)
ALX Oncology Inc. (3) · University of Colorado, Denver (1)
United States (4) · South Korea (3) · France (2) · Italy (2) · Singapore (2) · Spain (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Canada (1) · Czechia (1) · Japan (1) · Taiwan (1)